RATIONAL DEVELOPMENT OF IMMUNE THERAPY FOR LOW-GRADE OVARIAN SEROUS CARCINOMA TO OVERCOME MEK INHIBITOR RESISTANCE
$720,000FY2019Department of the ArmyDOD
The Univeristy Of Texas M.D. Anderson Cancer Center
The Univeristy Of Texas M.D. Anderson Cancer Center